Hologic to Acquire Focal Therapeutics for $125 Million, Strengthening Breast Surgery Franchise


Sep 26, 2018--Hologic, Inc. , a global leader in women's health, announced today that it has signed a definitive agreement to acquire Focal Therapeutics, a privately-held company, for $125 million in cash. In conjunction with Hologic's recent acquisition of Faxitron Bioptics, Focal strengthens the Company's position in the rapidly growing market for breast conserving surgery.



from Biotech News